Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)

In this certainly biased retrospective comparison, NC demonstrated superior ORR and longer PFS compared to PA in mRCC. These findings underscore the importance of considering individual patient characteristics and risk profiles when selecting first-line therapy for mRCC.

Authors

Institutions

Publication Details

Journal
Cancer Immunology Immunotherapy
Published
2025-05-27
DOI
https://doi.org/10.1007/s00262-025-04043-x
Citations
1
Primary Topic
Renal cell carcinoma treatment
Type
article
Field-Weighted Citation Impact
1.52

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)

Maria Teresa Bourlon, Martina Catalano, Ondřej Fiala, Martin Pichler et al.
1 citations
Cancer Immunology Immunotherapy
Renal cell carcinoma treatment
1.52
article

Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)

Maria Teresa Bourlon, Martina Catalano, Ondřej Fiala, Martin Pichler, Linda Cerbone, Zin Myint, Pasquale Rescigno, Sebastiano Buti, Camillo Porta, Dipen Bhuva, Matteo Santoni, Thomas Büttner, Orazio Caffo, Nuno Vau, Jakub Kucharz, Ravindran Kanesvaran, Giandomenico Roviello, Enrique Grande, Javier Molina‐Cerrillo, Emmanuel Seront, Jindřich Kopecký, Aristotelis Bamias, Kaisa Sunela, Maria Giuseppa Vitale, Ray Manneh Kopp, Caterina Gianni, Francesco Massari, Alfonso Gómez de Liaño, Zsófia Kürönya, Ugo De Giorgi, Anca Florina Zgura, Renate Pichler, Umberto Basso, Jawaher Ansari, Tomáš Büchler, Álvaro Pinto
article en
1 citations

Abstract

In this certainly biased retrospective comparison, NC demonstrated superior ORR and longer PFS compared to PA in mRCC. These findings underscore the importance of considering individual patient characteristics and risk profiles when selecting first-line therapy for mRCC.

Cancer Immunology ImmunotherapyVol. 74(7)
Champalimaud Foundation (PT), University of Modena and Reggio Emilia (IT), University of Parma (IT), Cliniques Universitaires Saint-Luc (BE), University of Kentucky (US), Innsbruck Medical University (AT), Universität Innsbruck (AT), National and Kapodistrian University of Athens (GR), Medical University of Graz (AT), Charles University (CZ), Hospital Universitario Insular de Gran Canaria (ES), University Hospital Bonn (DE), Hospital Universitario La Paz (ES), Markey Cancer Center (US), Popular University of Cesar (CO), Tawam Hospital (AE), Ospedale Santa Chiara (IT), Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT), Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX), University Hospital in Motol (CZ), Istituto Oncologico Veneto (IT), Azienda USL di Bologna (IT), National Institute of Oncology (HU), National Cancer Centre Singapore (SG), University Hospital Hradec Králové (CZ), The Maria Sklodowska-Curie National Research Institute of Oncology (PL), Finnish Medicines Agency Fimea (FI), Carlo Forlanini Hospital (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), MD Anderson Cancer Center Madrid (ES), Hospital Universitario Ramón y Cajal (ES), Army Hospital Research and Referral (IN), Ospedale di Macerata, University of Florence (IT), Newcastle University (GB)
Università degli Studi di Firenze
Good health and well-being
Openalex Percentile: Top 18%
Renal cell carcinoma treatment
1.52
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.